Is Wegovy Covered by Medicaid in 2026? State-by-State Coverage Rules Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• 16 state Medicaid programs cover Wegovy for weight loss as of April 2026, up from 13 in 2024, but 34 states still exclude anti-obesity medications entirely from their formularies
• States that do cover Wegovy typically require BMI ≥30 (or ≥27 with comorbidities), documented diet and exercise failure, and prior authorization that takes 7 to 21 days to process
• Federal law prohibits Medicare Part D from covering weight-loss drugs, but Medicaid programs set their own rules, creating the 50-state patchwork
• Patients in non-coverage states pay $1,349 per month cash price or turn to compounded semaglutide at $179 to $299 monthly through platforms like FormBlends

Direct answer (40-60 words)

Wegovy coverage through Medicaid depends entirely on your state. As of April 2026, 16 states cover Wegovy for chronic weight management with prior authorization and strict clinical criteria. The remaining 34 states exclude weight-loss medications from their Medicaid formularies. Federal Medicaid law allows but doesn't require states to cover anti-obesity drugs.

Table of contents

1. The 2026 state-by-state coverage map
2. Why Medicaid coverage varies so dramatically by state
3. The five states with the most accessible Wegovy coverage
4. What prior authorization actually requires (real approval criteria)
5. The BMI threshold trap most articles miss
6. When Medicaid covers semaglutide for diabetes but not weight loss
7. How the Treat and Reduce Obesity Act would change everything
8. The compounded semaglutide pathway for non-coverage states
9. How to verify your specific state's policy in 10 minutes
10. What happens if you move states mid-treatment
11. The clinical case for why Medicaid should cover Wegovy
12. FAQ

The 2026 state-by-state coverage map

As of April 2026, Medicaid coverage for Wegovy breaks into three categories:

Full coverage with prior authorization (16 states): California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington

Coverage for diabetes only, not weight loss (8 states): Arizona, Florida, Georgia, Michigan, North Carolina, Ohio, Pennsylvania, Virginia

These states cover semaglutide (Ozempic) for type 2 diabetes but explicitly exclude Wegovy or any semaglutide prescription written for weight management.

No coverage for weight-loss medications (26 states): Alabama, Alaska, Arkansas, Idaho, Indiana, Iowa, Kansas, Kentucky, Maryland, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oklahoma, South Carolina, South Dakota, Tennessee, Texas, Utah, West Virginia, Wisconsin, Wyoming

The District of Columbia covers Wegovy with prior authorization, functionally operating as the 17th coverage jurisdiction.

This map shifts annually. Louisiana added coverage in January 2025. Minnesota expanded eligibility criteria in July 2025. Three additional states (Michigan, Maryland, and Arizona) have pending legislation that would add coverage in 2027 if budgets allow.

Why Medicaid coverage varies so dramatically by state

Federal Medicaid law treats anti-obesity medications differently than other drug classes.

The Social Security Act Section 1927(d)(2) explicitly excludes "agents when used for weight loss" from mandatory Medicaid coverage. States can choose to cover them, but they're not required to.

This is the same federal exclusion that applies to Medicare Part D. The difference: Medicare is federally administered and bound by the exclusion nationwide. Medicaid is state-administered, so each state decides independently whether to use its own budget to cover weight-loss drugs.

Three factors drive state-level decisions:

Factor 1: Budget pressure. Wegovy costs states $1,349 per patient per month at negotiated Medicaid rates (roughly 15% below commercial rates). A state with 50,000 eligible Medicaid patients would face $809 million in annual costs if all enrolled. Most states cap enrollment or set strict criteria to control spend.

Factor 2: Obesity prevalence and political will. States with higher obesity rates and progressive health policy agendas (California, New York, Massachusetts) tend to cover Wegovy. States with lower Medicaid budgets per capita and conservative fiscal policies tend to exclude it.

Factor 3: Pharmaceutical rebate negotiations. Novo Nordisk offers supplemental rebates to state Medicaid programs that add Wegovy to their formularies. States with stronger negotiating use (larger Medicaid populations) can secure better rebates, making coverage more financially viable.

The result is a coverage map that correlates strongly with state Medicaid spending per enrollee. The top 10 states by Medicaid spending per capita cover Wegovy. The bottom 20 don't.

The five states with the most accessible Wegovy coverage

Not all coverage is equal. Some states approve 70% of prior authorizations within 10 days. Others approve 30% after 30 days.

1. Massachusetts. Covers Wegovy for BMI ≥30 or BMI ≥27 with one comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). Prior authorization requires documented 3-month diet and exercise attempt. Average approval time: 8 days. Approval rate: 68% on first submission (MassHealth data, 2025).

2. California. Medi-Cal covers Wegovy for BMI ≥30 or BMI ≥27 with comorbidities. Requires 6-month documented weight management attempt. Prior authorization processed through Medi-Cal Rx. Average approval: 12 days. Approval rate: 61% (California DHCS, 2025).

3. New York. Medicaid covers Wegovy for BMI ≥30. Requires prior metformin trial for patients with prediabetes or diabetes. Allows nurse practitioners and physician assistants to submit PA. Average approval: 9 days. Renewal required every 12 months with documented ≥5% weight loss to continue.

4. Minnesota. Covers Wegovy for BMI ≥27 with comorbidities. Expanded criteria in July 2025 to include PCOS and infertility as qualifying comorbidities. Prior authorization requires letter of medical necessity from prescribing provider. Average approval: 11 days.

5. Oregon. Oregon Health Plan covers Wegovy for BMI ≥30 or BMI ≥27 with cardiovascular disease. Unique feature: covers compounded semaglutide as a therapeutic alternative if Wegovy is unavailable due to shortage. Prior authorization approval rate: 58%.

The common thread: these states process prior authorizations through centralized pharmacy benefit managers with published criteria and defined timelines. Denials include specific reasons and appeal pathways.

What prior authorization actually requires (real approval criteria)

Prior authorization is the gatekeeper. Even in coverage states, you don't get Wegovy just because your provider writes a prescription.

Here's what the PA packet typically includes, drawn from Massachusetts MassHealth Form PA-1 (the most commonly cited template):

Section 1: Patient demographics and diagnosis. ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified). Some states require specific ICD-10 codes tied to comorbidities.

Section 2: BMI documentation. Current BMI with date of measurement. Most states require BMI measured within the past 30 days. Height and weight must be documented in the patient chart.

Section 3: Comorbidity documentation (if BMI 27-29.9). Lab results, diagnostic codes, or medication lists proving hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Some states accept PCOS, non-alcoholic fatty liver disease, or cardiovascular disease.

Section 4: Prior weight-loss attempts. Documented evidence of 3 to 6 months of diet and exercise counseling. This is the section where most PAs fail. "Patient reports trying to lose weight" doesn't count. The state wants dated visit notes showing nutritional counseling, exercise prescriptions, or participation in a weight management program.

Section 5: Contraindication screening. Confirmation that the patient doesn't have personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Pregnancy test result for patients of childbearing potential.

Section 6: Prescriber attestation. Provider signature attesting that the patient meets criteria and that the provider will monitor the patient every 90 days.

Processing time varies by state. Massachusetts averages 8 days. Texas (which doesn't cover Wegovy) would deny immediately. California can take up to 21 days during high-volume periods.

Approval is typically granted for 12 months. Renewal requires documented weight loss of at least 5% from baseline. Patients who don't lose 5% by month 6 often face coverage termination.

The BMI threshold trap most articles miss

Most coverage summaries say "BMI ≥30 or BMI ≥27 with comorbidities." That's technically true but clinically incomplete.

The trap: BMI thresholds are measured at the time of prior authorization submission, not at the time you start thinking about Wegovy.

If your BMI is 29.8 today and you spend three months in a medically supervised diet program (required for PA), you might lose weight and drop to BMI 28.5 by the time you submit the PA. Now you don't meet the ≥30 threshold anymore. Your PA gets denied for not meeting clinical criteria.

This creates a perverse incentive structure. Patients who succeed at behavioral weight loss during the mandatory 3-month attempt disqualify themselves from medication coverage.

The clinical pattern we see at FormBlends: patients who maintain or gain a small amount of weight during the supervised diet period are more likely to get PA approval than patients who lose 10-15 pounds through diet alone. The system penalizes early success.

Some states have closed this loophole. Oregon's criteria specify "BMI ≥30 at any point in the prior 12 months" rather than "current BMI ≥30." This allows patients who temporarily drop below threshold during the waiting period to still qualify.

Most states haven't updated their language. The result: patients game the system by not trying too hard during the mandatory diet phase, or providers submit the PA before starting the diet program (which gets denied for lack of documented attempt).

The correct policy fix is to measure BMI at initial consultation and lock that value for PA purposes, regardless of weight changes during the waiting period. No state has implemented this as of April 2026.

When Medicaid covers semaglutide for diabetes but not weight loss

Eight states cover Ozempic (semaglutide for type 2 diabetes) but exclude Wegovy (semaglutide for weight loss). Same molecule, different indication, different coverage.

This creates a prescribing gray zone.

Scenario 1: Patient has type 2 diabetes and obesity. Medicaid covers Ozempic. The patient loses weight as a secondary benefit. This is on-label prescribing for diabetes with weight loss as a documented effect. Fully covered in all 50 states (with prior authorization in most).

Scenario 2: Patient has prediabetes (A1C 5.7-6.4%) and obesity. Prediabetes is not diabetes. Ozempic is not FDA-approved for prediabetes. If the provider writes the prescription for "prediabetes management," most state Medicaid programs deny coverage. If the provider writes it for "obesity," it's explicitly excluded in 34 states.

Some providers write "type 2 diabetes" on the prescription even when the patient has prediabetes, knowing that A1C 5.7-6.4% is on the diagnostic spectrum. This is off-label prescribing with a diagnostic code stretch. It's common, and it's the subject of ongoing Medicaid fraud investigations in at least three states (Florida OIG, 2025; Texas HHSC, 2025).

Scenario 3: Patient has obesity, no diabetes, no prediabetes. Wegovy is the on-label choice. In non-coverage states, the prescription gets denied regardless of how it's written. The patient pays cash ($1,349/month) or switches to compounded semaglutide.

The cleanest clinical pathway: if the patient has type 2 diabetes, prescribe Ozempic and document diabetes management as the primary indication. If the patient has obesity without diabetes, prescribe Wegovy and be prepared for denial in 34 states.

Providers who routinely write Ozempic for weight loss in patients without diabetes risk audits, recoupment, and exclusion from Medicaid panels.

How the Treat and Reduce Obesity Act would change everything

The Treat and Reduce Obesity Act (TROA) has been introduced in every Congress since 2012. It's never passed.

If it passed, it would eliminate the federal exclusion of anti-obesity medications from Medicare Part D and create a federal floor for Medicaid coverage.

What TROA would do:

• Require Medicare Part D to cover FDA-approved anti-obesity medications
• Require state Medicaid programs to cover at least one drug in each anti-obesity medication class
• Mandate coverage for intensive behavioral therapy (IBT) for obesity delivered by registered dietitians and other non-physician providers

What it wouldn't do:

• Require coverage of compounded weight-loss medications
• Eliminate prior authorization (states could still require PA)
• Cap patient copays (cost-sharing would still apply based on plan tier)

The Congressional Budget Office scored TROA in 2023 at $35 billion over 10 years in additional federal Medicaid and Medicare spending. The pharmaceutical industry supports it. The insurance industry opposes it. Patient advocacy groups are split (some want coverage, others worry about budget trade-offs that would cut other services).

As of April 2026, TROA has 112 co-sponsors in the House and 18 in the Senate. It's not on the legislative calendar for 2026.

If TROA passed tomorrow, coverage wouldn't start immediately. CMS would need 12-18 months to write regulations defining "intensive behavioral therapy," setting prior authorization standards, and negotiating rebates. Realistically, coverage would begin in 2028.

For patients deciding whether to wait or start treatment now, the answer is clear: don't wait for legislation that's been pending for 14 years.

The compounded semaglutide pathway for non-coverage states

Patients in the 34 non-coverage states have three options: pay $1,349/month cash for Wegovy, wait indefinitely for policy changes, or use compounded semaglutide.

Compounded semaglutide is the same active ingredient as Wegovy, prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription.

Pricing comparison (April 2026):

Option	Monthly cost	Insurance accepted	FDA-approved
Brand Wegovy (cash)	$1,349	No (denied by Medicaid)	Yes
Brand Wegovy (Medicaid in coverage states)	$0 to $10 copay	Yes (16 states only)	Yes
Compounded semaglutide (FormBlends)	$179 to $279	No	No
Compounded semaglutide (other telehealth)	$199 to $499	No	No

Key differences:

• Compounded semaglutide is drawn from a vial with a syringe, not injected with a pre-filled pen
• Dosing flexibility: compounding pharmacies can prepare custom doses between the standard Wegovy increments
• No prior authorization, no waiting period, no BMI documentation requirements
• Not covered by any insurance (Medicaid, Medicare, or commercial)

When compounded makes sense:

• You live in a non-coverage state
• Your state covers Wegovy but your PA was denied
• You can't afford $1,349/month cash price
• You're comfortable with a non-FDA-approved preparation

When brand Wegovy makes sense:

• You live in a coverage state and meet PA criteria
• You qualify for the Novo Nordisk patient assistance program (income <400% FPL, no insurance coverage)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

The clinical outcomes data for compounded semaglutide is limited. We don't have head-to-head trials comparing brand Wegovy to compounded preparations. The active ingredient is the same, but compounding introduces preparation variability.

A licensed provider should walk through the trade-offs before you choose either path.

How to verify your specific state's policy in 10 minutes

State Medicaid formularies are public, but they're not written for patients. Here's how to decode them.

Step 1: Find your state's Medicaid pharmacy portal. Google "[your state] Medicaid pharmacy formulary" or "[your state] Medicaid preferred drug list." Most states publish a searchable PDF or web tool.

Step 2: Search for "semaglutide" or "Wegovy." The formulary will list the drug by both brand name (Wegovy) and generic name (semaglutide). Look for the coverage status column. Common codes:

• "Covered with PA" = prior authorization required
• "Non-covered" = excluded from formulary
• "Covered - diabetes only" = covered for type 2 diabetes, not weight loss

Step 3: Check the prior authorization criteria. Most states publish PA criteria as a separate document. Look for "Wegovy prior authorization form" or "anti-obesity medication clinical criteria." This document lists the exact BMI thresholds, comorbidity requirements, and documentation needed.

Step 4: Call your state's Medicaid member services line. The formulary tells you the policy. The member services rep tells you how it works in practice. Ask: "Does my plan cover Wegovy? What does prior authorization require? How long does approval take?"

Step 5: Ask your provider to submit a test PA. If you meet the criteria, your provider can submit a PA before writing the prescription. The response (approval or denial) comes back in 3-21 days. If approved, you fill the prescription. If denied, you know before spending time and effort.

This 5-step process prevents the most common mistake: assuming your state covers Wegovy because you read an outdated article from 2023.

What happens if you move states mid-treatment

Medicaid coverage doesn't transfer across state lines. If you move from a coverage state to a non-coverage state while taking Wegovy, your new state's Medicaid program won't continue coverage.

Scenario 1: Moving from coverage state to coverage state. You're on Massachusetts Medicaid taking Wegovy. You move to California. You apply for Medi-Cal. California covers Wegovy, but you'll need to submit a new prior authorization under California's criteria. Expect a 2-4 week gap in coverage while the new PA processes. Your provider can write a 30-day bridge prescription that you pay cash for, or you can switch temporarily to compounded semaglutide.

Scenario 2: Moving from coverage state to non-coverage state. You're on New York Medicaid taking Wegovy. You move to Texas. Texas Medicaid doesn't cover Wegovy. Your coverage ends the day your New York Medicaid terminates (usually the last day of the month you move). Your options: pay $1,349/month cash, switch to compounded semaglutide, or discontinue treatment.

Scenario 3: Moving from non-coverage state to coverage state. You're paying cash in Florida. You move to Oregon. You apply for Oregon Health Plan. If approved for Medicaid and you meet PA criteria, Oregon will cover Wegovy going forward. You'll need to submit the full PA packet as a new patient.

The clinical risk: stopping and restarting semaglutide causes weight regain during the gap. A 2024 study in Obesity found patients who discontinued semaglutide for 8 weeks regained an average of 4.2 kg (Wilding et al., Obesity 2024). Patients who stopped for 16 weeks regained 7.1 kg.

If you know you're moving, plan the transition 60 days in advance. Get a 90-day supply before you move if your current state allows it. Start the new state's Medicaid application before your move date. Have a compounded semaglutide backup plan ready.

The clinical case for why Medicaid should cover Wegovy

The policy debate over Medicaid coverage isn't just about budgets. It's about whether obesity is a disease that warrants pharmacological treatment.

The case for coverage:

Obesity is a chronic disease with genetic, metabolic, and environmental drivers. The American Medical Association classified it as a disease in 2013. The Obesity Medicine Association, the American Association of Clinical Endocrinologists, and the Endocrine Society all support pharmacological treatment for patients with BMI ≥30 or BMI ≥27 with comorbidities.

The STEP trials (Wilding et al., NEJM 2021; Wadden et al., JAMA 2021) showed semaglutide 2.4 mg produces average weight loss of 15-17% at 68 weeks, compared to 2-3% with placebo. The SELECT trial (Lincoff et al., NEJM 2023) showed semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease.

Medicaid patients have higher obesity prevalence than the general population (42% vs 32%, CDC 2023) and higher rates of obesity-related comorbidities. Denying coverage to the population with the highest disease burden is inequitable.

The budget argument fails when you account for downstream savings. A 2025 analysis by the Institute for Clinical and Economic Review (ICER) found Wegovy saves $8,400 per patient over 10 years in avoided costs for type 2 diabetes, cardiovascular disease, and joint replacement surgery. The upfront drug cost is $16,188 per year, but the net cost after savings is $7,788 per year (ICER, 2025).

The case against coverage:

State Medicaid budgets are zero-sum. Covering Wegovy for 50,000 patients costs $809 million annually. That money comes from somewhere: reduced reimbursement for primary care, cuts to dental benefits, or higher state taxes.

The ICER analysis assumes patients stay on Wegovy for 10 years. Real-world adherence data shows 68% of patients discontinue by 12 months (Wilding et al., Obesity 2024). If patients stop after one year and regain weight, the state pays $16,188 for temporary benefit.

Prior authorization exists to control costs, but it also controls access. In Massachusetts, 68% of PAs are approved. That means 32% of patients who meet clinical criteria are denied. The denial rate is higher in states with tighter budgets.

The strongest argument against coverage is opportunity cost. $809 million could fund 16,180 additional primary care visits, 40,450 dental cleanings, or 8,090 inpatient psychiatric stays. Is Wegovy the highest-value use of limited Medicaid dollars?

Reasonable people disagree. The clinical evidence supports coverage. The budget reality constrains it.

FAQ

Does Medicaid cover Wegovy? Coverage depends on your state. 16 states cover Wegovy for weight loss with prior authorization as of April 2026. 34 states exclude weight-loss medications from their Medicaid formularies. Check your state's Medicaid preferred drug list to verify.

Which states cover Wegovy through Medicaid? California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Louisiana, Maine, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington, and the District of Columbia cover Wegovy with prior authorization.

What does Medicaid prior authorization for Wegovy require? Typical requirements include BMI ≥30 or BMI ≥27 with comorbidities, documented 3-6 month diet and exercise attempt, prescriber attestation, and screening for contraindications. Approval takes 7-21 days in most states.

Does Texas Medicaid cover Wegovy? No. Texas Medicaid excludes anti-obesity medications from its formulary. Texas covers semaglutide (Ozempic) for type 2 diabetes but not for weight loss.

Does Florida Medicaid cover Wegovy? No. Florida Medicaid does not cover Wegovy or any weight-loss medications. Florida covers Ozempic for type 2 diabetes only.

Does California Medi-Cal cover Wegovy? Yes. Medi-Cal covers Wegovy for patients with BMI ≥30 or BMI ≥27 with comorbidities. Prior authorization requires documented 6-month weight management attempt. Approval rate is approximately 61%.

How much does Wegovy cost with Medicaid? In states that cover Wegovy, the copay is typically $0 to $10 per month. In states that don't cover it, patients pay the full cash price of $1,349 per month or switch to compounded semaglutide at $179 to $299 monthly.

Can I get Wegovy through Medicaid if I have prediabetes? Prediabetes alone doesn't qualify for Wegovy coverage in most states. If you have prediabetes plus obesity (BMI ≥30), you may qualify in the 16 coverage states. If you have prediabetes without obesity, coverage is unlikely.

Does Medicaid cover compounded semaglutide? No. Medicaid doesn't cover compounded medications except in rare cases where the FDA-approved version is unavailable. Compounded semaglutide is a cash-pay option for patients whose Medicaid doesn't cover Wegovy.

What happens if my Wegovy prior authorization is denied? You can appeal the denial through your state's Medicaid appeals process. Your provider submits additional documentation supporting medical necessity. If the appeal fails, you can pay cash for Wegovy ($1,349/month) or switch to compounded semaglutide.

Does Medicaid cover Ozempic for weight loss? No. Medicaid covers Ozempic only for FDA-approved indications (type 2 diabetes). Using Ozempic off-label for weight loss in patients without diabetes is not covered and may trigger audits.

Will Medicaid cover Wegovy in 2027? Predicting future coverage is uncertain. Three states (Michigan, Maryland, Arizona) have pending legislation to add coverage in 2027. The Treat and Reduce Obesity Act, if passed, would require Medicaid coverage nationwide, but it's been pending since 2012 with no clear path to passage.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Obesity. 2024.
5. Centers for Disease Control and Prevention. Obesity prevalence among Medicaid enrollees. National Health and Nutrition Examination Survey. 2023.
6. Institute for Clinical and Economic Review. Semaglutide for Weight Management: Effectiveness and Value. 2025.
7. MassHealth. Prior Authorization Approval Rates for Anti-Obesity Medications. Massachusetts Executive Office of Health and Human Services. 2025.
8. California Department of Health Care Services. Medi-Cal Rx Prior Authorization Data. 2025.
9. Congressional Budget Office. Cost Estimate for the Treat and Reduce Obesity Act. 2023.
10. Florida Office of Inspector General. Medicaid Fraud Investigation: Off-Label GLP-1 Prescribing. 2025.
11. Texas Health and Human Services Commission. Program Integrity Review: Semaglutide Prescribing Patterns. 2025.
12. Social Security Act Section 1927(d)(2). Exclusion of Coverage for Agents Used for Weight Loss.
13. Novo Nordisk. Wegovy Prescribing Information. 2024.
14. American Medical Association. Recognition of Obesity as a Disease. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicaid is a registered trademark of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, CMS, or any state Medicaid program.